Skip to content
Screener

Investing Cash Flow at other companies

Amgen logo
AmgenAMGN
-$569M-46.3%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
-$8K+96.0%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$137.82M-1,000%
PVL
Palvella TherapeuticsPVLA
-$55.44M
Regenxbio logo
RegenxbioRGNX
$65.93M+147%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$31.45M+164%

Other financials

Income statement

See full
Revenue$284.0K+279%
Operating income-$126.3M-18.3%
Net income-$127.1M-26.2%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$165.0M+40.6%
Total debt$114.4M+395%
Total equity$662.1M+28.5%
Total assets$1.1B+88.4%

Cash flow

See full
Operating cash flow-$105.3M-39.7%
CapEx$1.3M+3,010%
Free cash flow-$106.6M-41.4%

Valuation

See full
Market cap$2.55B+81.7%
Enterprise value$2.5B+90.9%
P/S35.9×-4,565×

Profitability

See full
Gross margin36.3%
Operating margin-569.7%-284pp
Net margin-544.1%-271pp
FCF margin-471%-235pp

Returns & leverage

See full
Return on equity-65.7%-0.1pp
Debt / equity0.2×+0.1×
Current ratio16.9×+5.9×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:31 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001590750-26-000018
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Purchases of marketable securities(469,975)(126,998)
Maturities of marketable securities317,408302,906
Purchase of property and equipment(1,329)(128)
Net cash provided by (used in) investing activities(153,896)175,780
Cash flows from financing activities:
Proceeds from the sale of convertible notes250,000
Proceeds from the issuance of common stock in offerings143,750
Proceeds from sale of common stock in at-the-market offerings4,944

Item 1. Financial Statements (Unaudited)

FAQ

What is Viridian Therapeutics, Inc.'s investing cash flow?
Viridian Therapeutics, Inc. (VRDN) reported investing cash flow of -$231.16M in Q2 2026.
How has Viridian Therapeutics, Inc.'s investing cash flow changed year-over-year?
Viridian Therapeutics, Inc.'s investing cash flow decreased by 405.3% year-over-year, from $75.72M to -$231.16M.
What is the long-term trend for Viridian Therapeutics, Inc.'s investing cash flow?
Over 3 years (2021 to 2025), Viridian Therapeutics, Inc.'s investing cash flow has grown at a -20.3% compound annual growth rate (CAGR), from -$74.29M to -$37.56M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Viridian Therapeutics, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude